You are here: Industry Insights > MTC

News List

CStone Announces NMPA Acceptance of New Drug Application of Selective Inhibitor GAVRETO(R) (Pralsetinib) with Priority Review Designation for the Treatment of Advanced or Metastatic RET-Altered Thyroi prnasia
April 28, 2021
CStone Pharmaceuticals, a leading biopharmaceutical company focused on developing and commercializing innovative immuno-oncology therapies and precision medicines, today announces that the National Medical Products Administration (NMPA) of China has ...
Roche gets FDA approval of Gavreto in advanced or metastatic RET-mutant and RET fusion-positive thyroid cancers pharmaceutical-business-review
December 07, 2020
Roche announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto (pralsetinib) for the treatment of adult and paediatric patients 12 years of age and older with advanced or metastatic rearranged during transfection (RET)-mutant ...
Genentech gets US FDA nod for Gavreto to treat RET-mutant, RET fusion-positive thyroid cancers expresspharma
December 03, 2020
Gavreto is a once-daily, oral precision therapy designed to selectively target RET alterations, including fusions and mutations.
US FDA approves Retevmo for lung, thyroid cancers with certain genetic mutations expresspharma
May 11, 2020
It is the first therapy approved specifically for cancer patients with the RET gene alterations.
Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer americanpharmaceuticalreview
January 02, 2020
Eli Lilly and Company announced the opening of the LIBRETTO-531 clinical trial for selpercatinib, also known as LOXO-292, for treatment-naïve RET-mutant medullary thyroid cancer (MTC) patients.
NICE turns down Sanofi's Caprelsa for rare thyroid cancer pharmafile
November 01, 2018
NICE has announced its recommendation to reject Sanofi’s Caprelsa (vandetanib) for use on the NHS in the treatment of medullary thyroid cancer (MTC) that either cannot be operated on or has metastasised to other areas of the body...